Mitratapide

Mitratapide
Systematic (IUPAC) name
2-[(2R)-Butan-2-yl]-4-[4-[4-[4-[[(2S,4R)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
Clinical data
Trade names Yarvitan
Identifiers
CAS Number 179602-65-4
ATCvet code QA08AB90(WHO)
PubChem CID 213047
ChemSpider 184740
UNII FVW7T75XP4
Synonyms Mitratapid; R103757
Chemical data
Formula C36H41ClN8O4S
Molar mass 717.28 g/mol

Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.[1] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[2]

The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.

See also

References

  1. Mitratapide, vetstream.com
  2. Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary research communications 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.